[PDF][PDF] Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical …
…, DF Bajorin, H Bleiberg, D Blum, D Hao… - Journal of clinical …, 2006 - academia.edu
Clinical Cancer Advances 2005 is the first independent annual review of the top advances
in cancer treatment, screening, and prevention across all cancer types. Produced by the …
in cancer treatment, screening, and prevention across all cancer types. Produced by the …
[HTML][HTML] Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment
D Hao, MO Sarfaraz, F Farshidfar, DG Bebb, CY Lee… - Metabolomics, 2016 - Springer
Lung cancer causes more deaths in men and women than any other cancer related disease.
Currently, few effective strategies exist to predict how patients will respond to treatment. We …
Currently, few effective strategies exist to predict how patients will respond to treatment. We …
[HTML][HTML] The gut microbiota: a potential gateway to improved health outcomes in breast cancer treatment and survivorship
K Sampsell, D Hao, RA Reimer - International Journal of Molecular …, 2020 - mdpi.com
Breast cancer is the most frequently diagnosed cancer in women worldwide. The disease
and its treatments exert profound effects on an individual’s physical and mental health. There …
and its treatments exert profound effects on an individual’s physical and mental health. There …
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor
D Hao, LA Hammond, SG Eckhardt, A Patnaik… - Clinical cancer …, 2003 - AACR
Purpose: The purpose of this study was to assess the feasibility and characterize the
pharmacokinetics of squalamine administered as a continuous iv infusion daily for 5 days every 3 …
pharmacokinetics of squalamine administered as a continuous iv infusion daily for 5 days every 3 …
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - Future Medicine
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell
lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. …
lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. …
Trends in the incidence of human papillomavirus–related noncervical and cervical cancers in Alberta, Canada: a population-based study
…, HY Lau, L Huang, C Doll, D Hao - … Medical Association Open …, 2014 - cmajopen.ca
Introduction Recent epidemiologic studies have suggested that the incidence of noncervical
cancers associated with human papillomavirus (HPV) is increasing. We assessed temporal, …
cancers associated with human papillomavirus (HPV) is increasing. We assessed temporal, …
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2019 - Future Medicine
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients
with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received …
with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received …
Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy
HY Lau, S Brar, AC Klimowicz, SK Petrillo, D Hao… - Head & …, 2011 - Wiley Online Library
Background Human papillomavirus (HPV)–related squamous cell cancer of the head and
neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be …
neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be …
[PDF][PDF] Pan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine …
…, H Anderson, RL Burkes, Q Chu, D Hao… - J Clin …, 2016 - metaphase-consulting.com
Purpose Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with
advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor …
advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor …
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642)
D Hao, JD Rizzo, S Stringer, RV Moore, J Marty… - Investigational new …, 2002 - Springer
Methyl-2-benzimidazolecarbamate(carbendazim, FB642) is an anticancer agentthat induces
apoptosis of cancer cells. Invitro, FB642 demonstrated potent antitumoractivity against both …
apoptosis of cancer cells. Invitro, FB642 demonstrated potent antitumoractivity against both …